iifl-logo

Aurobindo Pharma Ltd Quarterly Results

1,044.1
(0.78%)
Sep 5, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Jun-2025Mar-2025Dec-2024Sept-2024Jun-2024

Gross Sales

7,791.77

8,381.12

7,893.15

7,646.21

7,457.65

Excise Duty

0

0

0

0

0

Net Sales

7,791.77

8,381.12

7,893.15

7,646.21

7,457.65

Other Operating Income

76.37

1

85.37

149.86

109.37

Other Income

107.22

134.81

158.88

136.3

220.93

Total Income

7,975.36

8,516.93

8,137.4

7,932.37

7,787.95

Total Expenditure

6,265.11

6,622.39

6,400.54

6,229.93

5,948.84

PBIDT

1,710.25

1,894.54

1,736.86

1,702.44

1,839.11

Interest

97.75

115.02

118.48

112.7

111.04

PBDT

1,612.5

1,779.52

1,618.38

1,589.74

1,728.07

Depreciation

405.7

444.43

418.53

382.28

404.18

Minority Interest Before NP

0

0

0

0

0

Tax

490.72

430.51

498.07

322.13

449.27

Deferred Tax

-108.12

1.75

-143.79

68.38

-43.6

Reported Profit After Tax

824.2

902.83

845.57

816.95

918.22

Minority Interest After NP

-0.55

-0.64

-0.24

-0.43

-1

Net Profit after Minority Interest

824.75

903.47

845.81

817.38

919.22

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

824.75

903.47

845.81

817.38

919.22

EPS (Unit Curr.)

14.2

15.56

14.56

14

15.69

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

400

0

0

0

0

Equity

58.08

58.08

58.08

58.08

58.59

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

21.94

22.6

22

22.26

24.66

PBDTM(%)

20.69

21.23

20.5

20.79

23.17

PATM(%)

10.57

10.77

10.71

10.68

12.31

Aurobindo Pharma: Related NEWS

Aurobindo Pharma Q1 Updates: Net Profit slips 10.20% y-o-y

The company announced an operating EBITDA of ₹1,603 Crore, registering a marginal decline of 1% year-on-year.

5 Aug 2025|01:15 PM
Read More
Top Stocks for Today - 5th August 2025

Here are some of the stocks that may see significant price movement today: LTIMindtree, Paytm, Aurobindo Pharma, etc.

5 Aug 2025|09:00 AM
Read More
Aurobindo Pharma to Acquire U.S.-based Lannett for $250 Million

Lannett is a legacy pharmaceutical firm founded in 1942.  It is headquartered in Trevose, Pennsylvania, brings with it a deep expertise in manufacturing complex generics.

31 Jul 2025|09:19 AM
Read More
Top Stocks for Today - 3rd July 2025

Here are some of the stocks that may see significant price movement today: FSN E-Commerce, Voltas Limited, Aurobindo Pharma, etc.

3 Jul 2025|06:42 AM
Read More
Aurobindo Pharma’s Arm CuraTeQ Gets MHRA Nod for Dyrupeg

Dyrupeg is used primarily to reduce the risk of infection in cancer patients undergoing chemotherapy.

26 Jun 2025|12:55 PM
Read More
Top Stocks for Today - 27th May 2025

Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.

27 May 2025|06:36 AM
Read More
Aurobindo Pharma Q4 Profit Slips Marginally to ₹903 Crore

Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis

26 May 2025|09:14 PM
Read More
Top Stocks for Today - 29th April 2025

Here are some of the stocks that may see significant price movement today: Gensol Engineering, Oberoi Realty, TVS Motor Company, etc.

29 Apr 2025|06:38 AM
Read More
Aurobindo Pharma Gets USFDA Nod for Leukemia Drug Dasatinib

Aurobindo Pharma is going to launch Dasatinib in Q1 FY26, which will be in line with its plans to enhance its oncology portfolio in the US generics market.

23 Apr 2025|01:24 PM
Read More
Aurobindo Pharma Gets 11 FDA Observations After US Plant Inspection

Following the audit, the US FDA issued a Form 483 with 11 observations at closure, which Aurobindo Pharma described as small procedural observations.

15 Apr 2025|12:29 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.